MedTrace Logo

Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency

NCT03593031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-02-25

No results posted yet for this study

Summary

Convergence insufficiency (CI) is a prevalent binocular vision disorder with symptoms that include double/blurred vision, eyestrain, and headaches when engaged in reading or other near work. CI is present in 4% of the population where approximately 27% of CI patients do not improve even with validated therapy. The project will quantitatively study changes in convergence eye movements and neural substrates before and after validated therapy in CI patients. This knowledge can lead to improvements in currently validated therapy, reduction in therapy sessions, and reduced healthcare costs.

Conditions

  • Convergence Insufficiency

Interventions

BEHAVIORAL

Office Based Vergence and Accommodative Therapy

Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • New Jersey Institute of Technology

    lead OTHER

Principal Investigators

  • Atam Dhawan, PhD · New Jersey Institute of Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-01
Primary Completion
2019-04-01
Completion
2020-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593031 on ClinicalTrials.gov